Edition:
India

Erytech Pharma SA (ERYP.PA)

ERYP.PA on Paris Stock Exchange

6.40EUR
15 Jul 2019
Change (% chg)

€0.02 (+0.31%)
Prev Close
€6.38
Open
€6.48
Day's High
€6.48
Day's Low
€6.34
Volume
13,168
Avg. Vol
31,783
52-wk High
€9.86
52-wk Low
€5.61

Summary

Name Age Since Current Position

Jean-Paul Kress

2019 Chairman of the Board

Gil Beyen

56 2019 Chief Executive Officer, Director

Jerome Bailly

2011 Deputy Chief Executive Officer - Chief Pharmacist

Eric Soyer

2015 Chief Financial Officer, Chief Operating Officer

Alexander Scheer

2016 Chief Scientific Officer

Alex Dusek

Vice President - Commercial Strategy

Jean-Sebastien Cleiftie

2017 Director of Business Development and Licensing

Iman El-Hariry

Chief Medical Officer

Sven Andreasson

67 2014 Independent Director - Representative of Galenos

Philippe Archinard

59 2013 Independent Director

Hilde Windels

54 2017 Independent Director - Representative of BVBA Hilde Windels

Biographies

Name Description

Jean-Paul Kress

Dr. Jean-Paul Kress, M.D. is appointed as Chairman of the Board of the Company, effective June 21, 2019. He was President and Chief Executive Officer and a member of the Board of Directors of Syntimmune from January 2018 until its acquisition by Alexion Pharmaceuticals in November 2018 for up to $1.2 billion. Prior to joining Syntimmune, Dr. Kress served as Executive Vice President, President of International and Head of Global Therapeutic Operations at Biogen Inc. Previously, Dr. Kress served as Senior Vice President, Head of North America at Sanofi Genzyme. From July 2011 to September 2015, Dr. Kress served as President and Chief Executive Officer of Sanofi Pasteur MSD, a leading European vaccine company. Prior to this, Dr. Kress worked at Gilead, Abbvie and Eli Lilly in senior commercial and business development roles in the United States and in Europe.

Gil Beyen

Mr. Gil Beyen is Chief Executive Officer, Director of the Company. He is no longer Chairman of the Company, effective June 21, 2019. He previously worked at the Company as Chairman of the Supervisory Board from 2012. Mr. Beyen co-founded TiGenix NV. He was Chief Executive Officer of TiGenix since its beginning in 2000 until June 2011. He obtained a Masters degree in Bioengineering from Katholieke Universiteit Leuven in 1984 and a Masters of Business Administration degree from the University of Chicago. Mr. Beyen currently also works as Manager of Gil Beyen BVBA and of AXXIS V&C BVBA, Director of Waterleau NV and Governmental Commissioner of VIB (a Flemish biotechnological institute).

Jerome Bailly

Mr. Jerome Bailly has been Deputy Chief Executive Officer - Chief Pharmacist of Erytech Pharma SA since December 21, 2011. A pharmacist by training, he was, before joining the Company in 2007, Head of QA/Production at Skyepharma and Aguettant pharmaceuticals. Mr. Bailly received a Pharm.D degree (Pharmacy) and an Engineering degree with an elective in Chemistry and Biopharmaceutical Engineering: cellular production from Ecole Polytechnique de Montreal.

Eric Soyer

Alexander Scheer

Dr. Alexander Scheer, Ph.D., has been Chief Scientific Officer of the Company since October 27, 2016. Dr. Scheer has over 15 years of experience in R&D and the life science industry. Prior to joining ERYTECH, he served as the Head of Research at Pierre Fabre in France, focused primarily on oncology and central nervous system research, and also served as a Deputy Head of Research at Pierre Fabre. Prior to joining Pierre Fabre, Dr. Scheer served as a Director, Global Research Informatics & Knowledge Management R&D and Project Leader, Neglected Diseases at Merck Serono in Switzerland where, among other responsibilities, he led Merck's program to develop drugs for neglected diseases in collaboration with the World Health Organization (WHO). He also served as Head of Molecular Screening and Cellular Pharmacology Department, Group Leader of Biochemical Pharmacology and Research Scientist at Serono. Dr. Scheer holds a B.Sc in Natural Sciences and M.Sc. in Chemistry, both from the University of Gottingen, and a Ph.D. in Chemistry and Biochemistry from the German Cancer Research Center.

Alex Dusek

Jean-Sebastien Cleiftie

Mr. Jean-Sebastien Cleiftie serves as Director of Business Development and Licensing of the Company. Mr. Cleiftie has 15 years of experience in drug development, life science venture capital, and business development and licensing within the U.S. and European biopharmaceutical ecosystem. Prior to joining ERYTECH, he served as Associate Vice-President, Global Business Development & Licensing at Sanofi in Paris, France, where he led licensing transactions across multiple therapeutic areas, financial valuation activities, and other strategic projects. Prior to joining Sanofi, Mr. Cleiftie was a Principal at Innoven Partners, a venture capital firm active as lead investor in healthcare and IT in Europe and the U.S. He was responsible for healthcare investment opportunity assessment, transaction execution, and active portfolio management, and led equity investments in a number of biotech and medtech companies which achieved successful exits. He started his career in drug development in the U.S. as a research scientist with Aventis (now Sanofi) in the fields of immunotherapy and gene therapy for cancer. Mr. Cleiftie earned a M.S. in Biological & Medical Sciences and a M.S. in Immunology from the University of Paris V, and received his M.B.A from Cornell University.

Iman El-Hariry

Sven Andreasson

Mr. Sven Andreasson has been Independent Director of Erytech Pharma SA since April 2, 2013. He is Member of the Nominating and Remuneration Committee as well as Member of the Audit Committee. He previously served at the Company as Vice Chairman of the Board. He was the former Chief Executive Officer of Active Biotech AB and Chief Executive Officer of Beta-Cell NV, as well as President and Vice President of mainly Swedish, United Kingdom, Belgian, French and German companies and President of the BioPharma division within the Pharmacia Corporation. He holds a Bachelors degree in Business Management and a Bachelors degree in Finance, both from the Stockholm School of Economics and Business Administration. He is currently also Chairman of Oil AB and Director of Cellastra.

Philippe Archinard

Mr. Philippe Archinard has served as Independent Director of Erytech Pharma SA since April 2, 2013. He is Chairman of Nominating and Remuneration Committee and Member of the Strategic Committee and the Audit Committee. He previously served at the Company as Member of the Supervisory Board from 2005. Prior to that, he worked as Chief Executive Officer of Innogenetics since March 2000. He holds an engineering degree in Chemical Engineering and a Doctorate in Philosophy degree in Biochemistry, both gained at Universite de Lyon, and he also graduated from a PMD management program at the Harvard University. He currently also holds several other posts, including Director, Chairman of the Board and Chief Executive Officer of Transgene, Director of Biomerieux and Chairman of BioAster, among others.

Hilde Windels

Ms. Hilde Windels has been Independent Director representing BVBA Hilde Windels on the Board of Erytech Pharma SA since June 27, 2017. She is Chairwoman of company's Audit Committee. She is currently Chairwoman of Mycartis and Chief Executive Officer and Director of Biocartis.